SABCS 2025 | TUXEDO-3: HER3-DXd after T-DXd in HER2+ breast cancer with CNS involvement
Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, discusses the post-hoc subanalysis of the Phase II TUXEDO-3 trial (NCT05865990) of patritumab deruxtecan (HER3-DXd) in patients with HER2-positive metastatic breast cancer and active brain metastases or leptomeningeal disease previously treated with trastuzumab deruxtecan (T-DXd). In this heavily pretreated population, HER3-DXd demonstrated encouraging intracranial and bicompartmental progression-free survival (PFS) exceeding 6 months, supporting the feasibility of sequential antibody-drug conjugate (ADC) strategies in central nervous system (CNS) disease. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2025 Meeting in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
